Table 2.
IRC-assessed best response
| Ofatumumab (n = 219) | Rituximab (n = 219) | |
|---|---|---|
| Best response, n (%) | ||
| CR | 36 (16) | 44 (20) |
| PR | 74 (34) | 100 (46) |
| Stable disease | 71 (32) | 50 (23) |
| Progressive disease | 22 (10) | 23 (11) |
| Not evaluable | 16 (7) | 1 (< 1) |
| Responder | ||
| Yes (CR + PR), n (%) | 110 (50) | 144 (66) |
| No, n (%) | 109 (50) | 75 (34) |
| 95% CI, % | 43, 57 | 59, 72 |
| P* | .0011 | |
| Test for homogeneity of odds ratios across strata for responder | ||
| P† | .77 |
CMH, Cochran-Mantel-Haenszel.
*
CMH test adjusted for stratum.
†
Test of homogeneity of odds ratios across planned stratum (Breslow-Day test).